Follow-The-Filings

Security · featured owners

AMRX Amneal Pharmaceuticals Cl A Ord

Health Care EQUITY Equity among managers we track

AMRX (Amneal Pharmaceuticals Cl A Ord) 13F ownership among featured managers we track. Figures are as-filed 13F, not free float.

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

SEC filings

Recent issuer filings from EDGAR · 18 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 1.01,2.01,2.03,3.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
8-K 1.01,2.02,3.02,7.01,9.01 Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 10 rows shown

Filed Form Detail Links
4 Period Sep 11, 2026 Filing Doc
4 Period Sep 1, 2026 Filing Doc
4 Period Aug 21, 2026 Filing Doc
4 Period Aug 13, 2026 Filing Doc
4 Period Aug 11, 2026 · 2 forms Filing Doc
4 Period Aug 12, 2026 Filing Doc
4 Period Aug 10, 2026 · 4 forms Filing Doc
4 Period May 11, 2026 Filing Doc
4 Period May 6, 2026 · 8 forms Filing Doc
4/A Period Mar 2, 2026 · 2 forms Filing Doc

Updated about 19 hours ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.39B $2.79B $3.02B
Gross profit $0.821B $1.02B $1.11B
Gross margin * 34.3% 36.5% 36.9%
Net income -$79.26M — $72.06M
Net margin * -3.3% — 2.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.38B $1.59B $1.91B
Total non-current assets * $2.09B $1.91B $1.77B
Total assets $3.47B $3.5B $3.68B
Total current liabilities $0.847B $1.13B $0.882B
Total non-current liabilities $2.56B $2.42B $2.79B
Total equity $19.78M -$109.27M -$70.79M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $345.58M $295.1M $339.99M
Cash from investing -$69.19M -$63M -$112.26M
Cash from financing -$212.57M -$211.79M -$31.53M
Net change in cash $63.88M $19.31M $194.52M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders